Published in Hum Mol Genet on October 20, 2004
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest (2008) 1.60
Infantile convulsions with paroxysmal dyskinesia (ICCA syndrome) and copy number variation at human chromosome 16p11. PLoS One (2010) 1.04
Genetic and phenotypic heterogeneity in sporadic and familial forms of paroxysmal dyskinesia. J Neurol (2012) 0.98
The genetics of dystonia: new twists in an old tale. Brain (2013) 0.98
Familial dyskinesia and facial myokymia (FDFM): Follow-up of a large family and linkage to chromosome 3p21-3q21. Am J Med Genet B Neuropsychiatr Genet (2009) 0.97
The genetics of dystonias. Adv Genet (2012) 0.96
Assessment of patients with isolated or combined dystonia: an update on dystonia syndromes. Mov Disord (2013) 0.96
Diagnosis and treatment of paroxysmal dyskinesias revisited. Ther Adv Neurol Disord (2008) 0.94
Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia. J Clin Invest (2012) 0.92
Mutations in PNKD causing paroxysmal dyskinesia alters protein cleavage and stability. Hum Mol Genet (2011) 0.85
Analyzing clinical and electrophysiological characteristics of Paroxysmal Dyskinesia. J Res Med Sci (2011) 0.83
New insights into the pathogenesis and therapeutics of episodic ataxia type 1. Front Cell Neurosci (2015) 0.83
The clinical and genetic heterogeneity of paroxysmal dyskinesias. Brain (2015) 0.82
The Chemical Biology of Human Metallo-β-Lactamase Fold Proteins. Trends Biochem Sci (2016) 0.81
Protein mutated in paroxysmal dyskinesia interacts with the active zone protein RIM and suppresses synaptic vesicle exocytosis. Proc Natl Acad Sci U S A (2015) 0.81
Long-term improvement of paroxysmal dystonic choreathetosis with acetazolamide. J Neurol (2006) 0.79
The role of glyoxalases for sugar stress and aging, with relevance for dyskinesia, anxiety, dementia and Parkinson's disease. Aging (Albany NY) (2011) 0.78
Systematic mutation analysis of seven dystonia genes in complex regional pain syndrome with fixed dystonia. J Neurol (2010) 0.77
Episodic Ataxias: Clinical and Genetic Features. J Mov Disord (2016) 0.76
Bioinformatic analysis of human CNS-expressed ion channels as candidates for episodic nervous system disorders. Neurogenetics (2007) 0.76
The epileptic and nonepileptic spectrum of paroxysmal dyskinesias: Channelopathies, synaptopathies, and transportopathies. Mov Disord (2017) 0.75
Paroxysmal hypnogenic dyskinesia is associated with mutations in the PRRT2 gene. Neurol Genet (2016) 0.75
A homozygous PIGN missense mutation in Soft-Coated Wheaten Terriers with a canine paroxysmal dyskinesia. Neurogenetics (2016) 0.75
Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion. Aging (Albany NY) (2017) 0.75
Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder. J Clin Invest (2017) 0.75
Medical treatment of dystonia. J Clin Mov Disord (2016) 0.75
Paroxysmal nonkinesigenic dyskinesia with tremor. Case Rep Neurol Med (2013) 0.75
Paroxysmal Dyskinesia in Border Terriers: Clinical, Epidemiological, and Genetic Investigations. J Vet Intern Med (2017) 0.75
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature (2004) 12.72
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A (2009) 8.25
CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature (2006) 7.17
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science (2007) 6.04
Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science (2005) 5.50
Blinding in randomised trials: hiding who got what. Lancet (2002) 5.47
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
dbCAN: a web resource for automated carbohydrate-active enzyme annotation. Nucleic Acids Res (2012) 4.91
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Allocation concealment in randomised trials: defending against deciphering. Lancet (2002) 4.71
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
The comparative safety of legal induced abortion and childbirth in the United States. Obstet Gynecol (2012) 4.50
Operon prediction using both genome-specific and general genomic information. Nucleic Acids Res (2006) 4.41
Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. Nature (2005) 4.39
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Generation of allocation sequences in randomised trials: chance, not choice. Lancet (2002) 4.35
Sample size calculations in randomised trials: mandatory and mystical. Lancet (2005) 4.30
Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation. BMJ (2013) 4.17
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med (2010) 4.07
Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity (2004) 4.00
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med (2011) 3.93
Estimating accuracy of RNA-Seq and microarrays with proteomics. BMC Genomics (2009) 3.87
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet (2002) 3.74
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc Natl Acad Sci U S A (2008) 3.65
Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol (2004) 3.65
DOOR: a database for prokaryotic operons. Nucleic Acids Res (2008) 3.50
Human tRNA-derived small RNAs in the global regulation of RNA silencing. RNA (2010) 3.40
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
The transcriptional repressor DEC2 regulates sleep length in mammals. Science (2009) 3.12
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol (2005) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis. J Mol Biol (2004) 3.05
Activin a efficiently specifies definitive endoderm from human embryonic stem cells only when phosphatidylinositol 3-kinase signaling is suppressed. Stem Cells (2007) 3.04
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Aligned single-crystalline Si nanowire arrays for photovoltaic applications. Small (2005) 2.98
3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med (2004) 2.96
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Electronic fetal monitoring as a public health screening program: the arithmetic of failure. Obstet Gynecol (2010) 2.89
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurol (2007) 2.88
Second-trimester abortion for fetal anomalies or fetal death: labor induction compared with dilation and evacuation. Obstet Gynecol (2011) 2.83
Lamin B1 duplications cause autosomal dominant leukodystrophy. Nat Genet (2006) 2.83
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet (2004) 2.75
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
PRIMEGENS: robust and efficient design of gene-specific probes for microarray analysis. Bioinformatics (2002) 2.65
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol (2009) 2.64
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet (2002) 2.62
Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet (2010) 2.61
Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med (2005) 2.57
Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol (2002) 2.55
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Atlas - a data warehouse for integrative bioinformatics. BMC Bioinformatics (2005) 2.51
Epidemiologic research using administrative databases: garbage in, garbage out. Obstet Gynecol (2010) 2.50
Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. Nat Immunol (2009) 2.49
Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest (2002) 2.48
Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med (2013) 2.47
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
MicroRNA, mRNA, and protein expression link development and aging in human and macaque brain. Genome Res (2010) 2.44
Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell (2010) 2.42
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Case-control studies: research in reverse. Lancet (2002) 2.38
Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med (2009) 2.34
Multiplicity in randomised trials II: subgroup and interim analyses. Lancet (2005) 2.34
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
Multiplicity in randomised trials I: endpoints and treatments. Lancet (2005) 2.32
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat (2006) 2.30
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
RAPTOR: optimal protein threading by linear programming. J Bioinform Comput Biol (2003) 2.27
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
EBI2 mediates B cell segregation between the outer and centre follicle. Nature (2009) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Diagnosis and treatment of abdominal cocoon: a report of 24 cases. Am J Surg (2009) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17